Patient characteristics, MRD results, and relapse incidence
| . | MRD, no. of relapse/no. of patients . | |||
|---|---|---|---|---|
| Total . | Negative . | Low* . | High† . | |
| All patients | 13/30 | 0/5 | 5/10 | 8/15 |
| Diagnosis | ||||
| T-cell ALL | 3/4 | 0/0 | 1/1 | 2/3 |
| Pre-B-cell ALL | 10/26 | 0/5 | 4/9 | 6/12 |
| Status at SCT | ||||
| CR1 | 4/16 | 0/3 | 3/7 | 1/6 |
| CR2 | 8/11 | 0/1 | 2/3 | 6/7 |
| CR3 | 1/3 | 0/1 | 0/0 | 1/2 |
| Cytogenetics | ||||
| Normal | 5/13 | 0/1 | 0/4 | 5/8 |
| t(9;22) | 1/7 | 0/2 | 1/2 | 0/3 |
| t(4;11) | 3/4 | 0/1 | 2/2 | 1/1 |
| Other abnormal | 3/5 | 0/1 | 2/2 | 1/2 |
| Failed | 1/1 | 0/0 | 0/0 | 1/1 |
| Donor | ||||
| HLA-identical sibling | 7/14 | 0/1 | 4/7 | 3/6 |
| MUD | 3/13 | 0/4 | 1/3 | 2/6 |
| MM sibling | 1/1 | 0/0 | 0/0 | 1/1 |
| MM unrelated | 2/2 | 0/0 | 0/0 | 2/2 |
| Conditioning | ||||
| Cy + TBI | 6/21 | 0/5 | 3/6 | 3/10 |
| Cy + fTBI | 4/5 | 0/0 | 1/2 | 3/3 |
| Bu + Cy | 3/4 | 0/0 | 1/2 | 2/2 |
| ATG/OKT-3 | 4/16 | 0/5 | 1/3 | 3/8 |
| GVHD prophylaxis | ||||
| MTX + CsA | 10/25 | 0/4 | 5/10 | 5/11 |
| MTX | 0/1 | 0/0 | 0/0 | 0/1 |
| CsA | 1/2 | 0/1 | 0/0 | 1/1 |
| MTX + CsA + TcD | 2/2 | 0/0 | 0/0 | 2/2 |
| GVHD | ||||
| No GVHD | 3/3 | 0/0 | 0/0 | 3/3 |
| Only cGVHD | 2/3 | 0/0 | 1/1 | 1/2 |
| Only aGVHD I/II | 6/9 | 0/1 | 3/3 | 3/5 |
| aGVHD + cGVHD | 2/15 | 0/4 | 1/6 | 1/5 |
| Recipient and donor | ||||
| Recipient age, y (median) | 13 (2-53) | 10 (7-17) | 19 (3-40) | 8 (2-53) |
| Donor age, y (median) | 28 (6-60) | 34 (15-37) | 22 (9-49) | 30 (6-60) |
| Recipient sex, M/F | 17/13 | 2/3 | 5/5 | 10/5 |
| Donor sex, M/F | 18/12 | 4/1 | 5/5 | 9/6 |
| Cell dose, 108/kg (median) | 3.0 (1.2-9.7) | 2.9 (2.4-3.6) | 3.6 (1.4-6.7) | 3.0 (1.2-9.7) |
| Days in remission before SCT (median) | 68 (19-355) | 66 (31-150) | 50 (11-355) | 75 (19-222) |
| . | MRD, no. of relapse/no. of patients . | |||
|---|---|---|---|---|
| Total . | Negative . | Low* . | High† . | |
| All patients | 13/30 | 0/5 | 5/10 | 8/15 |
| Diagnosis | ||||
| T-cell ALL | 3/4 | 0/0 | 1/1 | 2/3 |
| Pre-B-cell ALL | 10/26 | 0/5 | 4/9 | 6/12 |
| Status at SCT | ||||
| CR1 | 4/16 | 0/3 | 3/7 | 1/6 |
| CR2 | 8/11 | 0/1 | 2/3 | 6/7 |
| CR3 | 1/3 | 0/1 | 0/0 | 1/2 |
| Cytogenetics | ||||
| Normal | 5/13 | 0/1 | 0/4 | 5/8 |
| t(9;22) | 1/7 | 0/2 | 1/2 | 0/3 |
| t(4;11) | 3/4 | 0/1 | 2/2 | 1/1 |
| Other abnormal | 3/5 | 0/1 | 2/2 | 1/2 |
| Failed | 1/1 | 0/0 | 0/0 | 1/1 |
| Donor | ||||
| HLA-identical sibling | 7/14 | 0/1 | 4/7 | 3/6 |
| MUD | 3/13 | 0/4 | 1/3 | 2/6 |
| MM sibling | 1/1 | 0/0 | 0/0 | 1/1 |
| MM unrelated | 2/2 | 0/0 | 0/0 | 2/2 |
| Conditioning | ||||
| Cy + TBI | 6/21 | 0/5 | 3/6 | 3/10 |
| Cy + fTBI | 4/5 | 0/0 | 1/2 | 3/3 |
| Bu + Cy | 3/4 | 0/0 | 1/2 | 2/2 |
| ATG/OKT-3 | 4/16 | 0/5 | 1/3 | 3/8 |
| GVHD prophylaxis | ||||
| MTX + CsA | 10/25 | 0/4 | 5/10 | 5/11 |
| MTX | 0/1 | 0/0 | 0/0 | 0/1 |
| CsA | 1/2 | 0/1 | 0/0 | 1/1 |
| MTX + CsA + TcD | 2/2 | 0/0 | 0/0 | 2/2 |
| GVHD | ||||
| No GVHD | 3/3 | 0/0 | 0/0 | 3/3 |
| Only cGVHD | 2/3 | 0/0 | 1/1 | 1/2 |
| Only aGVHD I/II | 6/9 | 0/1 | 3/3 | 3/5 |
| aGVHD + cGVHD | 2/15 | 0/4 | 1/6 | 1/5 |
| Recipient and donor | ||||
| Recipient age, y (median) | 13 (2-53) | 10 (7-17) | 19 (3-40) | 8 (2-53) |
| Donor age, y (median) | 28 (6-60) | 34 (15-37) | 22 (9-49) | 30 (6-60) |
| Recipient sex, M/F | 17/13 | 2/3 | 5/5 | 10/5 |
| Donor sex, M/F | 18/12 | 4/1 | 5/5 | 9/6 |
| Cell dose, 108/kg (median) | 3.0 (1.2-9.7) | 2.9 (2.4-3.6) | 3.6 (1.4-6.7) | 3.0 (1.2-9.7) |
| Days in remission before SCT (median) | 68 (19-355) | 66 (31-150) | 50 (11-355) | 75 (19-222) |
MUD indicates matched unrelated donor; MM, mismatch; Cy, cyclophosphamide; fTBI, fractionated total body irradiation; Bu, busulfan; OKT, orthoclone; ATG, antithymocyte globulin; GVHD, GVH disease; MTX, methothrexate; CsA, cyclosporine A; TcD, T-cell depletion; a/cGVHD, acute/chronic GVHD.
MRD < 10−3.
MRD = 10−2-10−3.